Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

iTeos Therapeutics, Inc. - Common Stock (NQ:ITOS)

10.18 +0.02 (+0.20%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 386,108
Open 10.16
Bid (Size) 10.16 (2)
Ask (Size) 10.24 (12)
Prev. Close 10.16
Today's Range 10.09 - 10.21
52wk Range 4.800 - 18.13
Shares Outstanding 35,763,742
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
iTeos Therapeutics To Wind Down Operations, Explores Asset Sale: Retail Believes It’s ‘Worth More Selling It Off’
The company decided to wind down operations as part of a review of strategic alternatives aimed at maximizing shareholder value after its collaboration with GSK plc ended. 
Via Stocktwits
Topics Intellectual Property

Performance

YTD
+28.9%
+28.9%
1 Month
N/A
N/A
3 Month
+93.9%
+93.9%
6 Month
+26.3%
+26.3%
1 Year
-27.4%
-27.4%

More News

Read More
These stocks are gapping in today's session
Via Chartmill
Heico, Monro, Abercrombie & Fitch, Joby Aviation And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
iTeos Therapeutics Announces Its Intention to Wind Down Operations
From iTeos Therapeutics Inc.
Via GlobeNewswire
This Wayfair Analyst Turns Bearish; Here Are Top 4 Downgrades For Wednesday
Via Benzinga
Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
iTeos Stock Soars Despite Trial Setback On Liquidation Buzz And Solid Cash Pile
Via Benzinga
iTeos, GSK End Collaboration On Experimental Cancer Therapy Development: But Retail’s Extremely Bullish
Via Stocktwits
Topics Government
iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates
From iTeos Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos Announces 2025 Strategic Priorities and Anticipated Milestones
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos to Participate in Upcoming Investor Conferences
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress
From iTeos Therapeutics Inc.
Via GlobeNewswire
The One-Minute Market Report - Sunday, Sept. 22
Via Talk Markets
Sky Harbour Group, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths
Via Investor's Business Daily
Topics Death
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
Via Benzinga
iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga

Frequently Asked Questions

Is iTeos Therapeutics, Inc. - Common Stock publicly traded?
Yes, iTeos Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does iTeos Therapeutics, Inc. - Common Stock trade on?
iTeos Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for iTeos Therapeutics, Inc. - Common Stock?
The ticker symbol for iTeos Therapeutics, Inc. - Common Stock is ITOS on the Nasdaq Stock Market
What is the current price of iTeos Therapeutics, Inc. - Common Stock?
The current price of iTeos Therapeutics, Inc. - Common Stock is 10.18
When was iTeos Therapeutics, Inc. - Common Stock last traded?
The last trade of iTeos Therapeutics, Inc. - Common Stock was at 07/03/25 01:00 PM ET
What is the market capitalization of iTeos Therapeutics, Inc. - Common Stock?
The market capitalization of iTeos Therapeutics, Inc. - Common Stock is 364.07M
How many shares of iTeos Therapeutics, Inc. - Common Stock are outstanding?
iTeos Therapeutics, Inc. - Common Stock has 364M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.